Role of Nova-1 in regulating alpha2N, a novel glycine receptor splice variant, in developing spinal cord neurons.
Inhibitory glycine receptor (GlyR) subunits undergo developmental regulation, but the molecular mechanisms of GlyR regulation in developing neurons are little understood. Using RT-PCR, we investigated the regulation of GlyR alpha-subunit splice forms during the development of the spinal cord of the rat. Experiments to compare the amounts of mRNA for two known splice variants of the GlyR alpha2 subunit, alpha2A and alpha2B, in the developing rat spinal cord revealed the presence of an additional, novel variant that lacked any exon 3, herein named "alpha2N." Examination of the RNA from spinal cords of different-aged rats showed a dramatic down-regulation of alpha2N during prenatal development: alpha2N mRNA formed a significant portion of the alpha2 subunit pool at E14, but its relative level was reduced by 85% by birth and was undetectable in adults. Two proteins previously implicated in regulating the splicing of GlyR alpha2 pre-mRNA, the neurooncological ventral antigen-1 (Nova-1) and the brain isoform of the polypyrimidine tract binding protein (brPTB), underwent small changes over the same period that did not correlate directly with the changes in the level of alpha2N, calling into question their involvement in the developmental regulation of alpha2N. However, treatment of spinal cord neurons in culture with antisense oligonucleotides designed selectively to knock down one of three Nova-1 variants significantly altered the relative level of GlyR alpha2N, showing that Nova-1 isoforms can regulate GlyR alpha2 pre-mRNA splicing in developing neurons. These results provide evidence for a novel splice variant of the GlyR alpha2 subunit that undergoes dramatic developmental regulation, reveal the expression profiles of Nova-1 and brPTB in the developing spinal cord, and suggest that Nova-1 plays a role in regulating GlyR alpha2N in developing neurons.
Department of Cell Biology & Anatomy, The University of Arizona, Tucson, Arizona 85724, USA.
David V
DV
Kumar
Alan
A
Nighorn
Paul A
PA
St  John
D017398:Alternative Splicing / Q000502:physiology*; D000818:Animals; D000951:Antigens, Neoplasm; D005260:Female; D018507:Gene Expression Regulation, Developmental; D009419:Nerve Tissue Proteins / Q000235:genetics; D000090682:Neuro-Oncological Ventral Antigen; D009474:Neurons / Q000502:physiology*; D038941:Polypyrimidine Tract-Binding Protein / Q000031:analogs & derivatives*; D011247:Pregnancy; D012333:RNA, Messenger / Q000032:analysis; D016601:RNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018009:Receptors, Glycine / Q000235:genetics* / Q000378:metabolism*; D012261:Ribonucleoproteins / Q000378:metabolism*; D013116:Spinal Cord / Q000166:cytology* / Q000196:embryology
D000951:Antigens, Neoplasm; C501173:Glra2 protein, mouse; C501174:Glra2 protein, rat; D009419:Nerve Tissue Proteins; D000090682:Neuro-Oncological Ventral Antigen; C429773:Ptbp2 protein, mouse; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D018009:Receptors, Glycine; D012261:Ribonucleoproteins; D038941:Polypyrimidine Tract-Binding Protein